Abstract
Melanoma is increasing rapidly in incidence and prevalence, especially in younger females and older males. Treatment options have expanded beyond high-dose interleukin 2 and adoptive T-cell therapy to include inhibitors of immune checkpoints programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and small molecular inhibitors of pathways activated in melanoma, in particular the mitogen-activated protein kinase (MAPK) pathway. PD-1/CTLA-4 inhibitors and inhibitors of MAPK such as BRAF/MEK inhibitors have significantly improved survival in both the metastatic and, more recently, adjuvant settings. In this review, we discuss the preclinical data, clinical development, and potential use of novel MEK inhibitor binemetinib, particularly in the setting of NRAS mutant melanoma.
Citations
May 21, 2020·International Journal of Molecular Sciences·Kevin YangAndrzej T Slominski
Sep 5, 2020·The Oncologist·Alexandra Valeska MatterSimone M Goldinger
Aug 21, 2020·British Journal of Pharmacology·Imke A K BurmesterRalf J Ludwig
Jul 7, 2019·Journal of Clinical Medicine·Valentina RossoDaniela Cilloni
Apr 2, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rahul SethPauline Funchain
May 12, 2020·British Journal of Cancer·Pawat PattarawatHwa-Chain Robert Wang
Apr 27, 2019·Frontiers in Immunology·Zvi Fishelson, Michael Kirschfink
Apr 3, 2019·International Journal of Molecular Sciences·Paola SavoiaOttavio Cremona
Oct 11, 2020·Cancers·Italia FalconeMichele Milella
Apr 4, 2021·Cancers·Meet PatelNeelu Puri
Apr 9, 2021·Cell Death & Disease·Keting BaoJian Li
May 1, 2021·International Journal of Molecular Sciences·Fabio ValentiAntonino Guerrisi
May 6, 2021·Journal of Personalized Medicine·Paula Martínez-FernándezInés Calabria
Jun 1, 2021·Signal Transduction and Targeted Therapy·Lei ZhongShengyong Yang
Jun 3, 2021·Life·Jiri Vachtenheim, Lubica Ondrušová
Jul 3, 2021·Cancers·Rossella PuglisiGianfranco Mattia